OOIR: Observatory of International Research

Papers

(The TQCC of Current Opinion in Allergy and Clinical Immunology is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
What molecular allergy teaches us about genetics and epidemiology of allergies	27
The use of environmental exposure chambers in studies related to ocular surface effects	26
The pathogenetic role of Th17 immune response in atopic dermatitis	22
Is immunotherapy safe for treatment of severe asthma	20
Economic burden of drug-induced anaphylaxis: what can we do better?	20
The collaborative medical practice of the ocular surface: a major role of the allergist/immunologist	20
Anaphylaxis due to antiallergic and antiasthmatic biologics	20
Liver disease in primary antibody deficiencies	19
Chronic spontaneous urticaria: new evidences on the role of autoimmunity	19
New approaches in childhood asthma treatment	19
Consequences of severe asthma exacerbations	19
E-cigarettes and asthma in adolescents	19
Drug allergy awareness and perspectives with the implementation of the International Classification of Diseases-11	19
Update on occupational allergy, including asthma, to soluble platinum salts	18
Mast cell conditions and drug allergy: when to suspect and how to manage	18
Atopic manifestations of inborn errors of immunity	18
Bronchiectasis and obstructive lung diseases in primary antibody deficiencies and beyond: update on management and pathomechanisms	18
Editorial introductions	17
Neuroimmune signalling pathways in chronic rhinosinusitis with nasal polyps	17
Real-world evidence of allergen immunotherapy	17
Editorial introductions	16
Epidemiology of the relationship between allergic bronchopulmonary aspergillosis and asthma	15
Perioperative anaphylaxis: when the allergological work-up goes negative	15
Ocular involvement in allergic drug reactions	15
Paucity of gastrointestinal plasma cells in common variable immunodeficiency	15

Is allergen immunotherapy a model of personalized treatment in pediatric respiratory allergy?	14
Transition of care in inborn errors of immunity	14
Editorial introductions	13
A review of food allergy-related costs with consideration to clinical and demographic factors	13
Editorial introductions	13
Updates in diagnosis and management of paediatric mastocytosis	13
Greater mechanistic understanding of the cutaneous pathogenesis of Stevens–Johnson syndrome/toxic epidermal necrolysis can shed light on novel therapeutic strategies: a comprehensive review	12
Health disparities in allergic diseases	12
Clinical remission in severe asthma: lights and shadows on an ambitious goal	12
Updates in school-based asthma management	12
Chronic rhinosinusitis with nasal polyps: eosinophils versus B lymphocytes in disease pathogenesis	12
Management and treatment of perioperative hypersensitivity	12
The complexity in DNA methylation analysis of allergic diseases	11
Food-labeling issues for severe food-allergic consumers	11
Biomarkers in the diagnosis of mast cell activation	10
Editorial introductions	10
Role of the ocular surface microbiome in allergic eye diseases	10
Food allergy: new therapeutic options open deeper questions	10
Update on hereditary C1q deficiency: pathophysiology, clinical presentation, genotype and management	10
What's new in pediatric asthma and rhinitis phenotypes and endotypes?	9
Strengthening the case for intralymphatic immunotherapy	9
Neurotrophic keratitis: inflammatory pathogenesis and novel therapies	9
Occupational respiratory allergy to reactive dyes	9
Atopic dermatitis and ocular allergy: common mechanisms and uncommon questions	9
Precision allergy molecular diagnosis applications in food allergy	9
Precision medicine to personalize medicine in allergic airway disease	9
Interstitial lung diseases in inborn errors of immunity	9
Do bacterial vaccines/adjuvants prevent wheezing episodes in children?	9
Monogenic forms of common variable immunodeficiency and implications on target therapeutic approaches	9
Immunobiologicals and ocular surface disease	9
Access from healthcare professionals to evidence-based pharmacotherapy in allergy management	9